(Total Views: 1055)
Posted On: 07/22/2020 11:50:51 PM
Post# of 155801
With the PE (primary endpoint) of our P2 M/M at 14 days, and many of the other secondaries at 14 days as well (including Duration of Hospitalization), it might be challenging to prove apples-to-apples superiority over remdesivir which cut recovery time for patients hospitalized with COVID-19 by 4 days.
Seems we don't have enough temporal resolution in many of the endpoints to compare and contrast.
Of course, I expect we will blow remdesivir away in a slew of other endpoints.
M/M Protocol Link: https://clinicaltrials.gov/ct2/show/NCT04343651
Seems we don't have enough temporal resolution in many of the endpoints to compare and contrast.
Of course, I expect we will blow remdesivir away in a slew of other endpoints.
M/M Protocol Link: https://clinicaltrials.gov/ct2/show/NCT04343651
(1)
(0)
